Morphos TECH Spółka z Ograniczoną Odpowiedzialnością (KRS 0001041195, NIP 8952258193) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. MORPHOS TECH operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since June 12, 2023. MORPHOS TECH's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Morphos TECH
Identity
- Name
- Morphos TECH Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 12, 2023
- Registry status as of
- July 3, 2026
- Latest entry
- July 3, 2026
- Founding act
- 07.06.2023 R.
Articles of association history (3)
- June 7, 2023: 07.06.2023 R.
- August 25, 2023: 25.08.2023 R., NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, UL. ŚWIĘTEGO ANTONIEGO 26, REP. A NR 2751/2023, UCHYLENIE DOTYCHCZASOWEGO TEKSTU UMOWY SPÓŁKI I UCHWALENIE NOWEGO BRZMIENIA.
- April 2, 2026: 02.04.2026 R., NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, UL. ŚWIĘTEGO ANTONIEGO 26, REP. A. NUMER 1143/2026, ZMIANA PAR. 4, 5, 6 UMOWY SPÓŁKI I PRZYJĘCIE NOWEGO TEKSTU JEDNOLITEGO.
Activities
Main activity
72.10.ZScientific research and development
Other activities
Address and contact
- Address
- UL. BIERUTOWSKA, 57-59, 51-317, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-70463-75462-CUUGD-28
Risk and payment profile - Morphos TECH
Credibility rating
54.4 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
11
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
1
1/3 yrs
Board changes
3
3/3 yrs
PKD changes
1
1/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: D (54/100)
Trend: stable (+0.3 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2023–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Morphos TECH
Founded
June 12, 2023
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
1 person
Proxies: 1
Filed years
2 years
2023–2024
Registry entries
14
latest: July 3, 2026
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
5.0 K PLN
2024
Equity
5.0 K PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Morphos TECH.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
